Lucid Diagnostics acquires lab assets from ResearchDx for up to $6.2M, launches LucidDx Labs; CMO resigns

Lucid Diagnostics Inc.

LucidDx Labs acquired licenses/assets from ResearchDx for up to $6.2M; $1.0M cash upfront, remainder contingent on license transfers and earnout.
LucidDx Labs will operate its own CLIA/CAP lab in Lake Forest, CA to perform EsoGuard testing, replacing RDx as testing provider.
LucidDx Labs entered a 3-year MSA with RDx for up to $1.8M in quarterly installments, plus lease at $71,465/month for lab space.
CMO David F. Wurtman resigned effective March 31, 2022; Brian J. deGuzman, MD (current Chief Compliance Officer) will assume duties.
Earnout payments may be made in cash or newly issued LUCD stock, not exceeding 19.99% of outstanding shares, exempt from registration.

item 1.01 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David F. Wurtman

Chief Medical Officer

LUCD · Lucid Diagnostics Inc.

Effective: 2022-03-31
Successor: Brian J. deGuzman
Filed: March 3, 2022, 6:59 PM ET

On March 1, 2022, David F. Wurtman, M.D. resigned from his position as Chief Medical Officer of the Company, effective as of March 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David F. Wurtman resigned as Chief Medical Officer at Lucid Diagnostics Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On March 1, 2022, David F. Wurtman, M.D. resigned from his position as Chief Medical Officer of the Company, effective as of March 31, 2022.

View on SEC.gov

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-005892

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.